GENFIT (EPA:GNFT) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
GENFIT

BRIEF

published on 09/19/2025 at 22:15, 2 months 15 days ago

GENFIT refocuses the development of VS-01 on a new pathology

Biopharmaceutical GENFIT ACLF VS-01 UCD
PRESS RELEASE

published on 09/19/2025 at 22:10, 2 months 15 days ago

GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
GENFIT discontinues VS-01 program in ACLF and shifts focus to UCD due to safety concerns. The company aims to accelerate other assets in ACLF, while exploring CCA data and reducing operating expenses

Clinical Trials GENFIT ACLF VS-01 UCD
BRIEF

published on 07/08/2025 at 22:15, 4 months 27 days ago

GENFIT Reports on Half-Year Liquidity Contract with Crédit Industriel et Commercial

Biopharmaceutical Liver Diseases Crédit Industriel GENFIT Liquidity 2025 Trading
PRESS RELEASE

published on 07/08/2025 at 22:10, 4 months 27 days ago

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
GENFIT announces half-year report of liquidity contract with Crédit Industriel et Commercial, detailing trading activities and resources as of June 30, 2025

Liquidity Contract Financial Report Crédit Industriel Et Commercial Trading Activities GENFIT
BRIEF

published on 06/17/2025 at 20:35, 5 months 17 days ago

GENFIT's Shareholder Meeting Approves Board's Resolutions

Biopharmaceuticals Resolutions Liver Diseases Shareholders Meeting GENFIT
PRESS RELEASE

published on 06/17/2025 at 20:30, 5 months 17 days ago

GENFIT: June 17, 2025 Combined Shareholders Meeting Results
GENFIT announces approval of all resolutions at June 17, 2025 Combined Shareholders Meeting. Exception: resolution n°28 rejected. Quorum: 27.21%

Resolutions Approval Quorum Shareholders Meeting GENFIT
BRIEF

published on 05/22/2025 at 22:15, 6 months 13 days ago

GENFIT: First Quarter 2025 Financial Results

Treasury Royalties GENFIT Iqirvo® Clinical Phase
PRESS RELEASE

published on 05/22/2025 at 22:10, 6 months 13 days ago

GENFIT Reports First Quarter 2025 Financial Information
GENFIT reports Q1 2025 financial information showing cash position growth and revenue increase. Details on Royalty Financing agreement, research efforts, and corporate governance update included

Financial Information Revenue Cash Position GENFIT Q1 2025
BRIEF

published on 05/20/2025 at 22:15, 6 months 15 days ago

GENFIT receives €26.5 million following a key milestone in Italy

Italy Primary Biliary Cholangitis GENFIT Milestone Payment Iqirvo®
PRESS RELEASE

published on 05/20/2025 at 22:10, 6 months 15 days ago

GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy
GENFIT to receive a €26.5 million milestone payment for pricing approval of Ipsen's Iqirvo® in Italy. This unlocks a new phase for pipeline progress in liver diseases

Approval GENFIT Milestone Payment Ipsen Iqirvo®

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 52 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 57 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 27 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 22 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 27 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 56 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 36 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 1 minute ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 12 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 16 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 27 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 42 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 42 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 26 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE